Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigations of a multi-objective diet optimization model including human health, environment, and observed dietary intake.

Food & nutrition research·2026
Same author

Potential Contribution of Plant-Based Milk Alternatives to the Nutrient Supply in Sustainable Diets.

Annals of nutrition & metabolism·2025
Same author

Protein intake and cardiovascular diseases: an umbrella review of systematic reviews for the evidence-based guideline on protein intake of the German Nutrition Society.

European journal of nutrition·2025
Same author

Urinary excretion of low- and no-calorie sweeteners (LNCS) and associated food sources, as observed in the German cross-sectional KarMeN-study.

European journal of nutrition·2025
Same author

A methodological framework for deriving the German food-based dietary guidelines 2024: Food groups, nutrient goals, and objective functions.

PloS one·2025
Same author

Data in Personalized Nutrition: Bridging Biomedical, Psycho-behavioral, and Food Environment Approaches for Population-wide Impact.

Advances in nutrition (Bethesda, Md.)·2025

Related Experiment Video

Updated: Jul 17, 2026

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

Inulin, oligofructose and immunomodulation.

Bernhard Watzl1, Stephanie Girrbach, Monika Roller

  • 1Institute of Nutritional Physiology, Federal Research Centre for Nutrition and Food, Haid-und-Neu-Strasse 9, 76131 Karlsruhe, Germany. bernhard.watzl@bfe.uni-karlsruhe.de

The British Journal of Nutrition
|May 10, 2005
PubMed
Summary

Prebiotics like inulin/oligofructose (IN/OF) activate immune cells in the gut, enhancing natural killer (NK) cell activity and potentially reducing tumor incidence in animal models. Human studies are needed to confirm these effects on systemic immunity.

More Related Videos

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
10:02

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

Related Experiment Videos

Last Updated: Jul 17, 2026

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota
07:15

An In Vitro Batch-culture Model to Estimate the Effects of Interventional Regimens on Human Fecal Microbiota

Published on: July 31, 2019

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma
10:02

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

Area of Science:

  • Immunology
  • Nutrition Science
  • Gastroenterology

Background:

  • Diet significantly influences immune function and infection resistance.
  • Non-digestible carbohydrates, such as prebiotics inulin/oligofructose (IN/OF), may impact the immune system, particularly the gut-associated lymphoid tissue (GALT).
  • Emerging evidence suggests IN/OF can modulate immune functions.

Purpose of the Study:

  • To review the effects of inulin/oligofructose (IN/OF) on immune functions, focusing on the gut-associated lymphoid tissue (GALT).
  • To explore the potential of IN/OF in modulating immune responses and its implications for disease, including cancer.
  • To identify gaps in current research, particularly regarding human studies on IN/OF and GALT.

Main Methods:

  • Review of animal studies investigating the impact of IN/OF on immune cell activation, cytokine production, and immune parameters in Peyer's patches and spleen.
  • Analysis of findings from limited human studies on IN/OF supplementation and systemic immune functions.
  • Examination of proposed mechanisms for IN/OF's immunomodulatory effects, including bacterial interactions and short-chain fatty acid (SCFA) production.

Main Results:

  • Animal studies show IN/OF activates immune cells in Peyer's patches, increasing IL-10 production and natural killer (NK) cell cytotoxicity.
  • IN/OF modulates secretory IgA, splenic NK cell activity, and splenocyte cytokine production in animals.
  • In animal tumor models, IN/OF was associated with a lower incidence of tumors, linked to enhanced GALT NK cell activity.
  • Human studies indicate IN/OF supplementation causes minor changes in systemic immunity, like reduced phagocytic activity.
  • No human data exists on IN/OF's effects on the GALT.

Conclusions:

  • IN/OF primarily modulates immune parameters within the GALT, with evidence of splenocyte activation.
  • The mechanisms involve potential direct effects of bacteria/bacterial components and SCFA production.
  • Further human research is essential to determine if IN/OF can modulate systemic immunity in well-nourished individuals and reduce disease risks like colon cancer.